HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

apratoxin S4

has antineoplastic activity; structure in first source

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Polycyclic Compounds: 6
- Macrocyclic Compounds: 15
  - Cyclic Peptides: 530
    - Depsipeptides: 297
      - apratoxin S4: 2
Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Cyclic Peptides: 530
    - Depsipeptides: 297
      - apratoxin S4: 2

Experts

1.	Chen, Qi-Yin: 2 articles (01/2021 - 01/2019)
2.	Luesch, Hendrik: 2 articles (01/2021 - 01/2019)
3.	Cai, Weijing: 1 article (01/2021)
4.	Dang, Long H: 1 article (01/2021)
5.	Law, Brian K: 1 article (01/2021)
6.	Raisch, Kevin P: 1 article (01/2021)
7.	Ratnayake, Ranjala: 1 article (01/2021)
8.	Wang, Mengxiong: 1 article (01/2021)
9.	Busoy, Joanna Marie: 1 article (01/2019)
10.	Cheng, Wei: 1 article (01/2019)

Related Diseases

1.	Triple Negative Breast Neoplasms 01/01/2021 - "This selectivity was most pronounced in breast cancer cells, where apratoxin S4 selectively targeted HER3 over HER2 and showed greater activity against ER+ and triple negative breast cancer cells than HER2+ cancer cells. "
2.	Choroidal Neovascularization 01/01/2019 - "Apratoxin S4 was also tested in mouse models of oxygen-induced retinopathy (OIR) and laser-induced choroidal neovascularization (CNV), and in a rabbit model of persistent retinal neovascularization (PRNV). "
3.	Retinal Neovascularization 01/01/2019 - "Apratoxin S4 was also tested in mouse models of oxygen-induced retinopathy (OIR) and laser-induced choroidal neovascularization (CNV), and in a rabbit model of persistent retinal neovascularization (PRNV). "
4.	Pancreatic Neoplasms (Pancreatic Cancer) 01/01/2021 - "Apratoxin S4 was active at low-nanomolar to sub-nanomolar concentrations against panels of lung, head and neck, bladder, and pancreatic cancer cells, concomitant with the downregulation of levels of several RTKs, including EGFR, MET and others. "
5.	Neoplasms (Cancer) 01/01/2021 - "We have profiled the synthetic, natural product-inspired apratoxin S4 against panels of cancer cells characterized by differential sensitivity to RTK inhibitors due to receptor mutations, oncogenic KRAS mutations, or activation of compensatory pathways. " 01/01/2021 - "This selectivity was most pronounced in breast cancer cells, where apratoxin S4 selectively targeted HER3 over HER2 and showed greater activity against ER+ and triple negative breast cancer cells than HER2+ cancer cells. "

Related Drugs and Biologics

1.	Proteins (Proteins, Gene)
2.	Oxygen (Dioxygen)

Related Therapies and Procedures

1.	Lasers (Laser)